8 Small-Cap Stocks Ripe for Solid Growth in 2019 - 1 of 8

 
 

#1 - Blackline (NASDAQ:BL)

Blackline (NASDAQ: BL) - Cloud computing continues to be one of the hot trends in the software industry, but that doesn’t mean the stocks are immune to the volatility that the rest of the market is experiencing. Stocks, such as Blackline (BL) have been punished lately, but where other SaaS companies have a higher profile, Blackline may be better positioned for growth. Blackline excels at generating revenue through a recurring subscription base that numbers in the thousands. What’s better still, that customer base is actually spending more while continuing to add new customers. As an investor, this means that the company is poised to deliver consistent financial results. In the last quarter, they posted an impressive 29% growth in revenue. Blackline’s management is estimating their current market is in excess of $18 billion compared to the $227 million it is estimated to generate in 2019. The company was recognized by Software Magazine as the seventh largest SaaS (Software-as-a-Service) providers. This is the eighth year in a row that the company has achieved this rank. The stock is currently trading slightly below the midpoint of its 52-week high and low. Current analyst rankings have the stock listed as a Moderate Buy. The company will deliver their fourth-quarter earnings report on February 14, 2019.

About BlackLine

BlackLine, Inc provides cloud-based solutions to automate and streamline accounting and finance operations worldwide. It offers financial close management solutions, such as account reconciliations that provides a centralized workspace for users to collaborate on account reconciliations; transaction matching that analyzes and reconciles individual transactions; task management to create and manage processes and task lists; and financial reporting analytics that enables analysis and validation of financial data. Read More 
Current Price
$60.83
Consensus Rating
Hold
Ratings Breakdown
3 Buy Ratings, 6 Hold Ratings, 2 Sell Ratings.
Consensus Price Target
$62.20 (2.3% Upside)

 

Better than Bitcoin? The Biotech Stock with 46,751% Potential (Ad)

4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.

Get the name of the stock here >>>